Dr. Jonathan C. Roberts, associate medical director and research director of the Bleeding and Clotting Disorders Institute in ...

Soleo Health has been named the exclusive in-network specialty pharmacy for Qfitlia (fitusiran) by Sanofi, the first ...

Sandi Tenza shares her journey with her son Sanda, diagnosed with haemophilia A, and the urgent need for awareness and ...

The Ministry of Health, in cooperation with the Royal Medical Services, Saturday launched the national report on hemophilia patients in Jordan. During a ceremony at the Jordan Health Forum, Health ...

Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United ...

Despite the challenges, including what CSL CEO Paul McKenzie has described as a fragmented U.S. healthcare system, the blood ...

Hemophilia is a genetic bleeding disorder where the blood doesn't clot properly due to a deficiency of clotting factors.

The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...

Sanofi has won US Food and Drug Administration (FDA) approval for haemophilia treatment Qfitlia (fitusiran), as the company aims to use the drug’s versatility to set it apart from rivals in a ...

“Today’s approval of Qfitlia is significant for patients with hemophilia because it can be administered less frequently than other existing options,” said Tanya Wroblewski, MD, deputy ...